猪尾猕猴体内混合CAR-T筛选鉴定出增殖、迁移和持久性增强的设计
在免疫健全的非人灵长类模型中,研究者构建20种含不同铰链、跨膜和共刺激结构域的CD20靶向CAR,混合后回输3只猪尾猕猴并纵向追踪。MyD88-CD40 CAR体外活化增强、细胞因子分泌独特、抗耗竭,体内扩增至占外周CAR-T的100%,优于CD28和4-1BB CAR,并伴B细胞耗竭;含CD28铰链和跨膜域的MyD88-CD40 CAR向次级淋巴组织迁移和持久性更优,其他CAR至第28天衰减。
要点
- 在3只猪尾猕猴中混合回输20种CD20 CAR-T,纵向追踪CAR丰度。
- MyD88-CD40 CAR体内扩增显著优于CD28和4-1BB CAR,最高占外周CAR-T的100%。
- 含CD28铰链和跨膜域的MyD88-CD40 CAR迁移至次级淋巴组织并持续至研究终点。
核心结论
- 非人灵长类模型可用于筛选CAR设计,MyD88-CD40 CAR为效力突出的候选。
研究设计与样本
- 在免疫健全非人灵长类模型中系统评估CAR结构功能关系,构建20种CD20靶向CAR,混合自体回输3只猪尾猕猴,用微滴数字PCR纵向追踪CAR丰度。
主要发现
- 体外,含MyD88-CD40共刺激域的CAR-T活化增加、细胞因子分泌独特、有强直信号并抗耗竭。
- 体内,MyD88-CD40 CAR大幅扩增,占外周CAR-T细胞最高达100%,显著优于经典CD28和4-1BB CAR。
- 该扩增在所有动物中均伴随强效B细胞耗竭。
- 含CD28铰链和跨膜域的MyD88-CD40 CAR向次级淋巴组织迁移更优并持续至研究终点,其他CAR至第28天衰减。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies; however, >60% of patients relapse within 1 year, often due to insufficient CAR-T persistence. Although mouse and primary cell models have been instrumental in advancing CAR-T therapy, they frequently fail to predict clinical outcomes, underscoring the need for more translationally relevant models. To address this limitation, we conducted, to our knowledge, the first systematic evaluation of CAR structure-function relationships in an immunocompetent nonhuman primate (NHP) model. We engineered an array of 20 CD20-targeted CARs with distinct combinations of hinge, transmembrane, and costimulatory domains. After ex vivo characterization, we administered pooled autologous CAR-T arrays to 3 NHPs and tracked CAR abundance longitudinally using a novel digital droplet polymerase chain reaction assay. Ex vivo, CAR-T cells incorporating the MyD88-CD40 costimulatory domain exhibited markedly distinct functional profiles, including increased activation, unique cytokine secretion, tonic signaling, and resistance to exhaustion. In vivo, MyD88-CD40 CARs expanded dramatically, comprising up to 100% of peripheral CAR-T cells and significantly outperforming canonical CD28- and 4-1BB-based CARs. This expansion was associated with robust B-cell depletion across all animals. MyD88-CD40 CARs, particularly those with a CD28 hinge and transmembrane domain, demonstrated superior trafficking to secondary lymphoid tissues and persistence through study end point, unlike other CARs, which waned by day 28. Our findings highlight the value of NHP models for screening CAR designs and identify MyD88-CD40 CARs as candidates with unmatched potency. The unique functional attributes conferred by this domain may provide key insights into features that drive enhanced CAR-T activity.
引用
- Maynard LH, Cavanaugh EJ, Zhu H, et al. Pooled CAR-T screening in pig-tailed macaques identifies designs with enhanced proliferation, trafficking, and persistence. Blood. 2025. PMID: 40811854. doi:10.1182/blood.2025028683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。